ID   TRPM7_HUMAN             Reviewed;        1865 AA.
AC   Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   05-OCT-2010, entry version 79.
DE   RecName: Full=Transient receptor potential cation channel subfamily M member 7;
DE            EC=2.7.11.1;
DE   AltName: Full=Channel-kinase 1;
DE   AltName: Full=Long transient receptor potential channel 7;
DE            Short=LTrpC-7;
DE            Short=LTrpC7;
GN   Name=TRPM7; Synonyms=CHAK1, LTRPC7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   MEDLINE=21279170; PubMed=11385574; DOI=10.1038/35079092;
RA   Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q.,
RA   Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M.,
RA   Fleig A.;
RT   "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for
RT   cell viability.";
RL   Nature 411:590-595(2001).
RN   [2]
RP   ERRATUM.
RA   Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q.,
RA   Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M.,
RA   Fleig A.;
RL   Nature 412:660-660(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=14594813; DOI=10.1074/jbc.M308820200;
RA   Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.;
RT   "Characterization of the protein kinase activity of TRPM7/ChaK1, a
RT   protein kinase fused to the transient receptor potential ion
RT   channel.";
RL   J. Biol. Chem. 279:3708-3716(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND
RP   VARIANT ILE-1482.
RC   TISSUE=Colon, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF LYS-1648 AND GLY-1799.
RX   PubMed=12887921; DOI=10.1016/S0092-8674(03)00556-7;
RA   Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K.,
RA   Penner R., Kurosaki T., Fleig A., Scharenberg A.M.;
RT   "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7.";
RL   Cell 114:191-200(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=15485879; DOI=10.1074/jbc.C400441200;
RA   Dorovkov M.V., Ryazanov A.G.;
RT   "Phosphorylation of annexin I by TRPM7 channel-kinase.";
RL   J. Biol. Chem. 279:50643-50646(2004).
RN   [8]
RP   INTERACTION WITH TRPM6.
RX   PubMed=14976260; DOI=10.1073/pnas.0305252101;
RA   Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H.,
RA   Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.;
RT   "Disruption of TRPM6/TRPM7 complex formation by a mutation in the
RT   TRPM6 gene causes hypomagnesemia with secondary hypocalcemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1404, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   VARIANT ILE-1482, AND CHARACTERIZATION OF VARIANT ILE-1482.
RX   PubMed=16051700; DOI=10.1073/pnas.0505149102;
RA   Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R.,
RA   Ryazanov A.G., Haymer D.S., Garruto R.M.;
RT   "A TRPM7 variant shows altered sensitivity to magnesium that may
RT   contribute to the pathogenesis of two Guamanian neurodegenerative
RT   disorders.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574;
RP   SER-720; VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306;
RP   LYS-1444 AND ILE-1482.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Essential ion channel and serine/threonine-protein
CC       kinase. Divalent cation channel permeable to calcium and
CC       magnesium. Has a central role in magnesium ion homeostasis and in
CC       the regulation of anoxic neuronal cell death. The kinase activity
CC       is essential for the channel function. May be involved in a
CC       fundamental process that adjusts plasma membrane divalent cation
CC       fluxes according to the metabolic state of the cell.
CC       Phosphorylates annexin A1 (ANXA1).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit (By similarity).
CC   -!- SUBUNIT: Homodimer. Interacts with PLCB1 (By similarity). Forms
CC       heterodimers with TRPM6.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein
CC       (Probable).
CC   -!- PTM: Autophosphorylated (By similarity).
CC   -!- DISEASE: Defects in TRPM7 are a cause of susceptibility to
CC       amyotrophic lateral sclerosis-parkinsonism/dementia complex type 1
CC       (ALS-PDC1) [MIM:105500]; also called amyotrophic lateral
CC       sclerosis-parkinsonism/dementia complex of Guam or Guam disease.
CC       Amyotrophic lateral sclerosis-parkinsonism/dementia complex type 1
CC       is a neurodegenerative disorder characterized by chronic,
CC       progressive and uniformly fatal amyotrophic lateral sclerosis and
CC       parkinsonism-dementia. Both diseases are known to occur in the
CC       same kindred, the same sibship and even the same individual.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the protein
CC       kinase superfamily. Alpha-type protein kinase family. ALPK
CC       subfamily.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the transient
CC       receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily.
CC   -!- SIMILARITY: Contains 1 alpha-type protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11462.1; Type=Erroneous initiation;
CC       Sequence=BAD18773.1; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY032950; AAK44211.1; -; mRNA.
DR   EMBL; AF346629; AAK19738.2; -; mRNA.
DR   EMBL; AK000124; BAA90958.1; -; mRNA.
DR   EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA.
DR   EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA.
DR   EMBL; BC051024; AAH51024.1; -; mRNA.
DR   IPI; IPI00290032; -.
DR   RefSeq; NP_060142.3; -.
DR   UniGene; Hs.512894; -.
DR   ProteinModelPortal; Q96QT4; -.
DR   SMR; Q96QT4; 1551-1830.
DR   MINT; MINT-2815126; -.
DR   STRING; Q96QT4; -.
DR   TCDB; 1.A.4.5.1; transient receptor potential Ca2+ channel (TRP-CC) family.
DR   TCDB; 1.A.4.5.6; transient receptor potential Ca2+ channel (TRP-CC) family.
DR   PhosphoSite; Q96QT4; -.
DR   PRIDE; Q96QT4; -.
DR   Ensembl; ENST00000313478; ENSP00000320239; ENSG00000092439.
DR   GeneID; 54822; -.
DR   KEGG; hsa:54822; -.
DR   UCSC; uc001zyt.2; human.
DR   CTD; 54822; -.
DR   GeneCards; GC15M050852; -.
DR   H-InvDB; HIX0012237; -.
DR   HGNC; HGNC:17994; TRPM7.
DR   MIM; 105500; phenotype.
DR   MIM; 605692; gene.
DR   Orphanet; 90020; Amyotrophic lateral sclerosis-parkinsonism-dementia complex.
DR   PharmGKB; PA38273; -.
DR   eggNOG; prNOG04714; -.
DR   HOGENOM; HBG505626; -.
DR   HOVERGEN; HBG055663; -.
DR   InParanoid; Q96QT4; -.
DR   OMA; NAYDNHV; -.
DR   OrthoDB; EOG97M4HN; -.
DR   PhylomeDB; Q96QT4; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 57577; -.
DR   ArrayExpress; Q96QT4; -.
DR   Bgee; Q96QT4; -.
DR   CleanEx; HS_TRPM7; -.
DR   Genevestigator; Q96QT4; -.
DR   GermOnline; ENSG00000092439; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005262; F:calcium channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008219; P:cell death; IEA:UniProtKB-KW.
DR   InterPro; IPR005821; Ion_trans.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR004166; MHCK_EF2_kinase.
DR   Pfam; PF02816; Alpha_kinase; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   SMART; SM00811; Alpha_kinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51158; ALPHA_KINASE; 1.
PE   1: Evidence at protein level;
KW   Amyotrophic lateral sclerosis; ATP-binding; Calcium; Calcium channel;
KW   Calcium transport; Coiled coil; Complete proteome; Ion transport;
KW   Ionic channel; Kinase; Membrane; Metal-binding; Neurodegeneration;
KW   Nucleotide-binding; Parkinsonism; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase; Transmembrane;
KW   Transmembrane helix; Transport; Zinc.
FT   CHAIN         1   1865       Transient receptor potential cation
FT                                channel subfamily M member 7.
FT                                /FTId=PRO_0000215331.
FT   TOPO_DOM      1    755       Cytoplasmic (Potential).
FT   TRANSMEM    756    776       Helical; (Potential).
FT   TOPO_DOM    777    855       Extracellular (Potential).
FT   TRANSMEM    856    876       Helical; (Potential).
FT   TOPO_DOM    877    918       Cytoplasmic (Potential).
FT   TRANSMEM    919    939       Helical; (Potential).
FT   TOPO_DOM    940    962       Extracellular (Potential).
FT   TRANSMEM    963    983       Helical; (Potential).
FT   TOPO_DOM    984    995       Cytoplasmic (Potential).
FT   TRANSMEM    996   1016       Helical; (Potential).
FT   TOPO_DOM   1017   1035       Extracellular (Potential).
FT   INTRAMEM   1036   1056       Pore-forming; (Potential).
FT   TOPO_DOM   1057   1074       Extracellular (Potential).
FT   TRANSMEM   1075   1095       Helical; (Potential).
FT   TOPO_DOM   1096   1865       Cytoplasmic (Potential).
FT   DOMAIN     1594   1824       Alpha-type protein kinase.
FT   NP_BIND    1794   1800       ATP (By similarity).
FT   COILED     1198   1250       By similarity.
FT   ACT_SITE   1767   1767       Proton acceptor (By similarity).
FT   METAL      1753   1753       Zinc (By similarity).
FT   METAL      1810   1810       Zinc (By similarity).
FT   METAL      1812   1812       Zinc (By similarity).
FT   METAL      1816   1816       Zinc (By similarity).
FT   BINDING    1624   1624       ATP (By similarity).
FT   BINDING    1648   1648       ATP (By similarity).
FT   BINDING    1720   1720       ATP (By similarity).
FT   BINDING    1769   1769       ATP (By similarity).
FT   BINDING    1777   1777       ATP (By similarity).
FT   MOD_RES    1404   1404       Phosphoserine.
FT   MOD_RES    1477   1477       Phosphoserine.
FT   MOD_RES    1493   1493       Phosphoserine (By similarity).
FT   VARIANT      68     68       G -> V (in dbSNP:rs56064201).
FT                                /FTId=VAR_042395.
FT   VARIANT     406    406       S -> C (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042396.
FT   VARIANT     459    459       I -> T (in dbSNP:rs55924090).
FT                                /FTId=VAR_042397.
FT   VARIANT     574    574       K -> N (in dbSNP:rs56040619).
FT                                /FTId=VAR_042398.
FT   VARIANT     720    720       T -> S (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042399.
FT   VARIANT     830    830       M -> V (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042400.
FT   VARIANT     949    949       F -> Y (in dbSNP:rs55681028).
FT                                /FTId=VAR_042401.
FT   VARIANT    1033   1033       A -> G (in dbSNP:rs34530969).
FT                                /FTId=VAR_052381.
FT   VARIANT    1064   1064       Q -> R (in dbSNP:rs56298128).
FT                                /FTId=VAR_042402.
FT   VARIANT    1145   1145       I -> V (in dbSNP:rs34711809).
FT                                /FTId=VAR_052382.
FT   VARIANT    1211   1211       I -> T (in dbSNP:rs56090496).
FT                                /FTId=VAR_042403.
FT   VARIANT    1254   1254       A -> V (in dbSNP:rs56288221).
FT                                /FTId=VAR_042404.
FT   VARIANT    1306   1306       D -> E (in dbSNP:rs55970334).
FT                                /FTId=VAR_042405.
FT   VARIANT    1444   1444       R -> K (in dbSNP:rs55840070).
FT                                /FTId=VAR_042406.
FT   VARIANT    1482   1482       T -> I (mutant channels are functional
FT                                but show increased susceptibility to
FT                                inhibition by intracellular magnesium
FT                                concentrations compared to wild-type
FT                                channels; dbSNP:rs8042919).
FT                                /FTId=VAR_019967.
FT   MUTAGEN    1648   1648       K->R: Loss of kinase activity.
FT   MUTAGEN    1799   1799       G->D: Loss of kinase activity.
FT   CONFLICT    573    575       EKM -> KKK (in Ref. 4; BAD18773).
FT   CONFLICT    998    998       A -> S (in Ref. 5).
FT   CONFLICT   1496   1496       Missing (in Ref. 3; AAK19738).
FT   CONFLICT   1520   1520       D -> V (in Ref. 3; AAK19738).
SQ   SEQUENCE   1865 AA;  212697 MW;  BE732674D52D7485 CRC64;
     MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM
     KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI
     LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV
     AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN
     LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV
     LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE
     ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV
     DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT
     KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL
     GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK
     KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR
     SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST
     CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA
     EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP
     ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK
     VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA
     GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA
     ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY
     LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS
     LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT
     FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV
     HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK
     DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK
     NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF
     VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS
     RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER
     NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG
     GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA
     AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP
     TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE
     DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS
     VRLML
//
